Tolododekin Alfa

托洛多白介素α

Report date: 2026/04/17 20:02:02

Base Information

Drug NameTolododekin Alfa
Drug Alias NameANK101ANK-101
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-12 receptor stimulants
TargetsInterleukin-12 receptor
Therapy Area/IndicationsRejection of renal transplantationSolid tumoursSoft Tissue Injuries +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnkyra Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAnkyra Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantationSolid tumoursSoft Tissue Injuries +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG